Home About us Contact
|
Home About us Contact | ||
|
|
||
Nodular Subtypes (nodular + subtype)
Selected AbstractsClinicopathologic significance of dysadherin expression in cutaneous malignant melanomaCANCER, Issue 8 2005Immunohistochemical analysis of 115 patients Abstract BACKGROUND The E-cadherin,mediated cell adhesion system is frequently inactivated by multiple mechanisms and is involved in tumor progression in many types of cancer. Recently, the authors reported a novel cell membrane glycoprotein, dysadherin, which has an anti,cell-cell adhesion function and down-regulates E-cadherin. METHODS Expression of both dysadherin and E-cadherin was investigated immunohistochemically in 115 patients with cutaneous malignant melanoma to determine the correlation between the 2 molecules and their associations with both patient survival and the clinicopathologic features of the tumors. RESULTS Dysadherin and E-cadherin were expressed at the cell membranes of melanoma cells. Fifty-two percent of the tumors showed dysadherin immunopositivity, and 91% of the tumors showed reduced E-cadherin immunopositivity. There was no significant inverse correlation between dysadherin expression and E-cadherin expression. Increased dysadherin expression was significantly correlated with nodular subtype (P = 0.042), Clark level (P < 0.001), tumor thickness (P < 0.001), ulceration (P = 0.008), lymph node metastasis (P < 0.001), high TNM classification (P < 0.001), and poor patient survival (P < 0.001). Multivariate analysis of patient survival revealed that increased dysadherin expression was a significant predictor of poor survival (P < 0.001). CONCLUSIONS Thus, increased expression of dysadherin was a significant indicator of poor prognosis in patients with cutaneous malignant melanoma. Cancer 2005. © 2005 American Cancer Society. [source] The effect of 595,nm pulsed dye laser on superficial and nodular basal cell carcinomasLASERS IN SURGERY AND MEDICINE, Issue 6 2009Sonali M. Shah MD Abstract Background and Objective Basal cell carcinomas (BCCs) have supporting vasculature that could serve as a target for 595,nm pulsed dye laser (PDL). The objective of this study was to determine the effect of repeated PDL treatments on BCCs of superficial and nodular subtypes and of varying diameters. Study Design/Materials and Methods Twenty biopsy-proven BCCs received four 595,nm PDL treatments at 2-week intervals. The tumor and 4,mm of peripheral skin were treated using a set of previously optimized laser parameters: one pass, 15,J/cm2 energy, 3,ms pulse length, no cooling, and 7,mm spot size with 10% overlap. The treated area was excised and evaluated histologically for residual tumor. Histologic response rates of the PDL treated BCCs were compared with that of non-PDL treated, matched control tumors. Results Nearly all BCCs <1.5,cm in diameter (n,=,12) showed complete response to four PDL treatments (91.7%; n,=,11/12) versus 16.7% of controls (n,=,2/12, P -value,= 0.0003). BCCs ,1.5,cm in diameter (n,=,8) showed a complete response rate of 25% (n,=,2/8) versus 0% of controls (n,=,0/8, P -value,=,0.2). Mean clinical tumor diameter of the complete responders was 1.1,cm (n,=,13) versus 2.2,cm (n,=,7) for incomplete responders (P -value,=,0.005). Tumor histologic types among the complete responders included superficial, nodular, micronodular, and keratinizing. Incompletely responding BCCs showed a significant reduction in tumor burden after PDL treatment, with residual histologic tumor burden ranging from <1% to 29% of the original clinical tumor diameter, compared to 13,68% residual tumor burden for the corresponding controls (P -value,=,0.05). Conclusions PDL is an effective means of reducing tumor burden in patients with large BCCs and may be an alternative therapy in BCCs <1.5,cm in diameter. Lasers Surg. Med. 41:417,422, 2009. © 2009 Wiley-Liss, Inc. [source] Expression of lumican, a small leucine-rich proteoglycan with antitumour activity, in human malignant melanomaCLINICAL & EXPERIMENTAL DERMATOLOGY, Issue 4 2007S. Brézillon Summary Background., The family of small leucine-rich proteoglycans (SLRPs), which includes decorin, lumican, biglycan and fibromodulin, constitutes an abundant component of the skin extracellular matrix. We previously demonstrated that human lumican inhibits melanoma growth and progression in a mouse experimental model, by regulating cell migration, proliferation and apoptosis. Aim., The aim of this study was to investigate the expression of lumican and decorin in human malignant melanoma and adjacent peritumoral tissue, to understand better their role in the control of growth and invasion of human melanoma. Methods., Expression of both proteoglycans was studied by immunohistochemistry using specific antibodies in 34 malignant melanomas, 12 Hutchinson's melanotic freckles and 4 cutaneous metastatic melanomas. Results., We showed that lumican and decorin are located in the dermis and in the peritumoral stroma of malignant melanoma, but are not found in melanoma cells or dense tumour tissue. In the healthy dermis, distant from the tumour, the increasing ratio of lumican to decorin was inversely correlated with the proliferation of the tumour cells (P = 0.035). The comparison of the level of expression of lumican protein in superficial vs. nodular subtypes of malignant melanomas showed a decrease of lumican but not decorin in the peritumoral stroma of nodular subtypes. In the peritumoral stroma, the level of expression of lumican but not decorin decreased significantly (P = 0.016) with increasing Clark levels. In addition, immunocytochemical and reverse transcription PCR analyses of malignant melanoma cell lines (A-375, HT-144) and of MRC-5 and dermal fibroblasts from healthy donors in vitro confirmed that dermal fibroblasts are responsible for lumican and decorin synthesis in skin. Conclusions., Lumican may regulate vertical progression of human malignant melanoma, but further study is necessary to clarify the antitumour mechanism and the downstream signal transduction pathways involved. [source] | ||||||||||